Secondary intraocular lens implantation by a single surgeon at a tertiary hospital: indications, techniques, outcomes and complications
Session Details
Session Title: Presented Poster Session: Cataract Complications Management
Venue: Poster Village: Pod 1
First Author: : H.Nithianandan CANADA
Co Author(s): : P. Morales R. Tan M. Taha K. Baig
Abstract Details
Purpose:
The aim of our study was to describe the indications, techniques, intra-operative complications, and outcomes of secondary intraocular lens (IOL) implantation by a single surgeon in a tertiary hospital anterior segment practice.
Setting:
The University of Ottawa Eye Institute in Canada.
Methods:
All patients who underwent secondary IOL implantation (alone or combined with IOL removal) between 2009 and 2016 were included in this retrospective case series study (n=145). The indications for the IOL, technique of implantation, intraoperative complications, and follow up visual acuities were recorded. The statistical analyses were performed using SPSS software version 20.0 (SPSS, Chicago Illinois, USA).
Results:
One hundred forty-five eyes (65% males) that underwent secondary IOL implantation were analyzed. The mean age of the participants included in this study was 61.7 (Standard Deviation:19.1) years. The common indications for the secondary IOLs included aphakia (70%), pseudophakic bullous keratopathy (12.5%), and uveitis-glaucoma-hyphema syndrome (5%). Implantation techniques included angle-fixated, sulcus-placed, scleral-sutured, intrascleral-fixated, transconjunctival-fixated, and artificial iris IOLs, with the most common being retropupillary iris-clipped (47.5%), and iris sutured (25%). Intraoperative complications were seen in 2% of the cases. Improvements in visual acuity at final follow-up were observed in 93% of cases.
Conclusions:
To our knowledge, this is the first study that reports the outcomes of a full spectrum of secondary IOL implantation techniques by a single surgeon. Secondary IOL implantation can be considered a safe option to improve vision for a variety of indications.
Financial Disclosure:
NONE
